



## THE EFFECTS OF AMIKACIN ON RED BLOOD CELL MEMBRANE STABILITY

Aiman Ehtisham<sup>1</sup>, Ruqaiya Hasan<sup>1\*</sup>, Mahanoor Nisar<sup>1</sup>, Maira Hasan<sup>2</sup>

<sup>1</sup>Department of Physiology, Faculty of Science, University of Karachi, Karachi- 75270, Pakistan.

<sup>2</sup>Hamdard University Hospital, Taj Medical Complex, M.A, Jinnah Road, Karachi, Pakistan.



\*Corresponding Author: Prof. Dr. Ruqaiya Hasan

Department of Physiology, Faculty of Science, University of Karachi, Karachi- 75270, Pakistan.

DOI: <https://doi.org/10.5281/zenodo.21019816>

**How to cite this Article:** Aiman Ehtisham<sup>1</sup>, Ruqaiya Hasan<sup>1\*</sup>, Mahanoor Nisar<sup>1</sup>, Maira Hasan<sup>2</sup>. (2026). The Effects of Amikacin On Red Blood Cell Membrane Stability. World Journal of Pharmaceutical and Life Sciences, 12(7), 68–71. This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 15/05/2026

Article Revised on 05/06/2026

Article Published on 01/07/2026

### ABSTRACT

**Background:** Physicians widely use Amikacin as an aminoglycoside antibiotic to treat severe gram-negative infections. However, researchers must further evaluate its interaction with non-targeted cells, such as erythrocytes.

**Objective:** To evaluate the impact of Amikacin on erythrocytes membrane integrity and hemolysis under controlled *in vitro* conditions. **Materials and Methods:** Washed human red blood cells were treated with increasing doses of Amikacin (25–200  $\mu\text{L}/\text{mL}$ ). Samples were maintained at 37 °C for 30 minutes, and red blood cells lysis was measured by spectrophotometer at 540 nm. Structural changes were evaluated microscopically.

**Results:** Erythrocytes destruction enhanced in a dose-related manner, with negligible impact at lower concentrations and considerable cell destruction at higher concentrations. Microscopy confirmed progressive structural alterations in red blood cells. **Conclusion:** The disruption of erythrocytes at high doses of Amikacin, highlighting the importance to evaluate the drug - cell reaction.

**KEYWORDS:** Amikacin, Red blood cells, Hemolysis, Membrane integrity, Aminoglycosides, Infections.

### INTRODUCTION

Antibiotics are important in clinical medicines to treat infections, but research is still under progress that how these drugs may affect the cells other than the intended target cells like red blood cells (RBCs). RBCs play an important role in oxygen transport and any damage to membrane integrity may lead to medical effects due to loss of physiological homeostasis.<sup>[1,2]</sup>

Aminoglycosides are potent, broad-spectrum antibiotics that act through inhibition of protein synthesis. However, the drug may interact with cellular surfaces and disrupt the membrane integrity under conditions including high concentration of drug, long- term exposure, or membrane with increased components of negative charges.<sup>[3,4]</sup> RBCs provide a well-accepted model for investigating the drug- induced alterations in the membrane structure.<sup>[5]</sup>

Amikacin is a semi-synthetic aminoglycoside, used to treat severe, resistant bacterial infections. It has well established antibacterial activity against a wide variety of

Gram-negative organisms.<sup>[6,7]</sup> However, it's potential effects on RBCs inducing osmotic fragility in dose - dependent manner requires further investigation.<sup>[8]</sup>

Among certain factors, one of the factor responsible for destruction of RBCs is the drug – induced hemolysis. This drug – dependent increased membrane fragility is associated with increased oxidative stress, either by generating reactive oxygen species or decreasing cellular antioxidant activity.<sup>[9,10]</sup> The evaluation of hemolytic activity under controlled laboratory conditions is crucial for the analysis of safety characteristics of the drug.

Therefore, this study aimed to evaluate the effect of Amikacin on RBC membrane stability and hemolysis under *in vitro* conditions.

### MATERIALS AND METHODS

#### Experimental Setup

Six treatment groups were established with Amikacin concentrations of 25, 50, 75, 100, 150, and 200  $\mu\text{L} / \text{mL}$ . Each concentration was tested in replicates to ensure

reliability.

### Blood Sampling and Preparation

Blood was drawn from healthy volunteers in EDTA tubes adhering to ethical standards and approved procedures. Erythrocytes were separated by centrifugation, washed with isotonic saline, and re-suspended to the desired concentration.<sup>[11]</sup>

### Drug Treatment

Amikacin was added to erythrocytes suspensions at the specified concentrations. A negative control (isotonic saline) and a positive control (distilled water) were included.

### Incubation

Samples were incubated at 37 °C for 30 minutes.

### Spectrophotometric Analysis

Post- incubation, samples were centrifuged and the supernatants were analyzed at 540 nm to quantify hemolytic activity.<sup>[12]</sup>

The experiments were performed with five different

samples independently to ensure reproducibility, and results are expressed as mean  $\pm$  SD.

### Microscopic study

Peripheral blood smears were prepared, and observed under microscope to evaluate cellular morphological alterations.

### Hemolysis Calculation

Hemolysis (%) was calculated by the formula:


$$\text{Hemolysis Rate (\%)} = (A_{\text{test}} - A_{\text{negative control}}) / (A_{\text{positive control}} - A_{\text{negative control}}) \times 100$$

Where, A = Absorbance

## RESULTS

### Spectrophotometric Findings

Hemolysis increased progressively with increasing concentrations of Amikacin. Lower concentrations (25–50  $\mu\text{L}/\text{mL}$ ) produced minimal hemolysis, whereas higher concentrations (150–200  $\mu\text{L}/\text{mL}$ ) resulted in marked RBC membrane damage. The data demonstrated a clear concentration-dependent trend.



**Fig. 1: Concentration-dependent hemolytic activity of Amikacin on human RBCs\***

\*Each value is the mean  $\pm$  SD of 5 samples.

Fig. 1 represented the effect of different concentrations of Amikacin on RBCs hemolysis. The hemolysis increased gradually with increasing doses, demonstrating a concentration - dependent trend. The lower doses (25–50  $\mu\text{L}/\text{mL}$ ) produced minimal hemolysis, whereas, higher doses (150–200  $\mu\text{L}/\text{mL}$ ) resulted in a significant destruction to RBCs membrane.

### Microscopic Observations

Fig. 2a – 2g represented the drug – induced morphological variations in erythrocytes. The RBCs placed in normal saline i.e., in negative control, appeared as biconcave (Fig.2a), whereas, the RBCs treated with higher concentrations of antibiotic (100, 150, and 200  $\mu\text{L}/\text{mL}$ ) showed membrane deformation, cellular swelling and disintegration of RBCs membranes (Fig. 2e, 2f, 2g).



Fig.2a: Isotonic Saline



Fig.2b: 25 µL/mL Amikacin



Fig. 2c: 50 µL/mL Amikacin




Fig. 2d: 75 µL/mL Amikacin




Fig. 2e: 100 µL/mL Amikacin



Fig. 2f: 150 µL/mL Amikacin




Fig. 2g: 200 µL/mL Amikacin.

Fig. 2: Drug- induced morphological alterations in erythrocytes.

## DISCUSSION

The increased destruction of RBCs, observed in the present study indicate the capability of Amikacin to disrupt the RBCs membrane stability at elevated doses. This effect may be attributed to interplay with cellular surface constituents, leading to structural fragility.<sup>[13,14]</sup>

The visible morphological changes in the RBCs structure are supported by the spectrophotometric results (Fig.1), confirming the gradual changes and damage to the erythrocyte membrane. These results are in consistence with the previous study where selected antibiotics interacted with RBCs membrane leading to morphological alterations.<sup>[15]</sup>

Redox imbalance and increased lipid peroxidation are the well- established mechanisms involved in the drug- induced immune hemolytic anemia, responsible for oxidative injury to erythrocytes components.<sup>[9,10]</sup> The

findings of the present study indicated that Amikacin is capable to induce both structural and functional impairments resulting in hemolysis.<sup>[14,16]</sup>

Moreover, the current studies suggested that hemolysis is strongly associated with decreased membrane flexibility and increased oxidative injury at cellular level.<sup>[17]</sup> Additionally, the emerging RBC - based drug interaction research highlights the crucial role of membrane stability in determining the response of RBCs to pharmacological agents.<sup>[18]</sup>

Erythrocytes serve as a sensitive model for studying foundational mechanism effects, and the present results reinforce the importance of evaluating this membrane targeting effect for systemic antibacterials.<sup>[5]</sup>

## CONCLUSION

Amikacin affects erythrocyte integrity in a dose-related

manner, with elevated amounts causing substantial RBCs destruction and physical damage. These findings highlight the requirement for further studies to better comprehend the pathways underlying drug- related membrane changes.

#### ACKNOWLEDGEMENT

Authors are thankful to the Chairperson, Department of Physiology, University of Karachi, for providing the facilities to accomplish this research.

#### REFERENCES

- Gallagher, P. G. Hemolytic Anemias: Red Blood Cell Membrane and Metabolic Defects. In *Goldman-Cecil Medicine*, 27th Edition., 2023; 1-2: 1093-1102.e1. Elsevier. <https://doi.org/10.1016/B978-0-323-93038-3.00147-7>
- Lutz, H. U., & Bogdanova, A. Mechanisms tagging senescent red blood cells for clearance in healthy humans. *Frontiers in physiology*, 2013; 4: 387. <https://doi.org/10.3389/fphys.2013.00387>
- Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. Aminoglycosides: An Overview. *Cold Spring Harbor perspectives in medicine*, 2016; 6(6): a027029. <https://doi.org/10.1101/cshperspect.a027029>
- Epand, R. M., & Epand, R. F. Lipid domains in bacterial membranes and the action of antimicrobial agents. *Biochimica et biophysica acta*, 2009; 1788(1): 289–294. <https://doi.org/10.1016/j.bbamem.2008.08.023>
- D'Alessandro, A. (2025). Red blood cell metabolism. In L. Kaestner & A. Bogdanova (Eds.), *Handbook of red blood cells*. Springer. [https://doi.org/10.1007/978-3-031-19369-9\\_9-1](https://doi.org/10.1007/978-3-031-19369-9_9-1)
- Raut, A., Sharma, D., & Suvarna, V. A Status Update on Pharmaceutical Analytical Methods of Aminoglycoside Antibiotic: Amikacin. *Critical reviews in analytical chemistry*, 2022; 52(2): 375–391. <https://doi.org/10.1080/10408347.2020.1803042>
- Yang, H., Huang, Z., Yue, J., Chen, J., Yu, M., & Qu, C. Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of *Pseudomonas aeruginosa*. *Frontiers in cellular and infection microbiology*, 2023; 13: 1327452. <https://doi.org/10.3389/fcimb.2023.1327452>
- Alnakshbandi A. A. Aminoglycosides induce fragility of human red cell membrane: an in vitro study. *Indian journal of pharmacology*, 2015; 47(1): 114–116. <https://doi.org/10.4103/0253-7613.150375>
- Langer, A. L. Oxidative hemolysis due to phenazopyridine in the absence of G6PD deficiency. *Blood*, 2024; 144(20): 2155. <https://doi.org/10.1182/blood.2024012345>
- Paika, S., Machini, M., & Parmar, M. S. Molecular Mechanisms of Drug-Induced Hemolysis in G6PD Deficiency: Mechanistic Insights. *Oxidative medicine and cellular longevity*, 2025; 2025: 7041213. <https://doi.org/10.1155/omcl/7041213>
- Zaidi, A. U., Buck, S., Gadgeel, M., Herrera-Martinez, M., Mohan, A., Johnson, K., Bagla, S., Johnson, R. M., & Ravindranath, Y. Clinical Diagnosis of Red Cell Membrane Disorders: Comparison of Osmotic Gradient Ektacytometry and Eosin Maleimide (EMA) Fluorescence Test for Red Cell Band 3 (AE1, SLC4A1) Content for Clinical Diagnosis. *Frontiers in physiology*, 2020; 11: 636. <https://doi.org/10.3389/fphys.2020.00636>
- Sæbø, I. P., Bjørås, M., Franzyk, H., Helgesen, E., & Booth, J. A. Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity. *International journal of molecular sciences*, 2023; 24(3): 2914. <https://doi.org/10.3390/ijms24032914>
- Huisjes, R., Bogdanova, A., van Solinge, W. W., Schiffelers, R. M., Kaestner, L., & van Wijk, R. Squeezing for Life - Properties of Red Blood Cell Deformability. *Frontiers in physiology*, 2018; 9: 656. <https://doi.org/10.3389/fphys.2018.00656>
- Baeva, E., Holyavka, M., Artyukhov, V., & Kondratyev, M. Structural Alterations of Human Erythrocytes Induced by Minocycline. *Cells*, 2025; 14(22): 1787. <https://doi.org/10.3390/cells14221787>
- Sriharini, S., Sugantha, B. S., & Selvaraj, S. Evaluation of dose-dependent interactions of antibiotics using RBC membrane model systems. *Recent Innovations in Chemical Engineering*, 2023; 16(3): 167–173. <https://doi.org/10.2174/2405520416666230815124135>
- Javaheri-Ghezeldizaj, F., Azimirad, M., Ghafouri, N., Zaheri, M., Yekta, R., Moghadaszadeh, M., Zeinolabedini, M., & Ezzati Nazhad Dolatabadi, J. Probing amikacin interaction with albumin: A combined multispectral and molecular docking investigation. *Heliyon*, 2024; 10(19): e38509. <https://doi.org/10.1016/j.heliyon.2024.e38509>
- Barshtein, G., Livshits, L., Gural, A., Arbell, D., Barkan, R., Pajic-Lijakovic, I., & Yedgar, S. Hemoglobin Binding to the Red Blood Cell (RBC) Membrane Is Associated with Decreased Cell Deformability. *International journal of molecular sciences*, 2024; 25(11): 5814. <https://doi.org/10.3390/ijms25115814>
- Nguyen, P. H. D., Jayasinghe, M. K., Le, A. H., Peng, B., & Le, M. T. N. Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles. *ACS nano*, 2023; 17(6): 5187–5210. <https://doi.org/10.1021/acsnano.2c11965>